※一部利用できない機能があります
Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib
- フォーマット:
- 論文
- 責任表示:
- Terashima, Takeshi ; Yamashita, Tatsuya ; Arai, Kuniaki ; Sunagozaka, Hajime ; Kitahara, Masaaki ; Nakagawa, Hidetoshi ; Kagaya, Takashi ; Mizukoshi, Eishiro ; Honda, Masao ; Kaneko, Shuichi
- 言語:
- 英語
- 出版情報:
- Blackwell Publishing / 日本肝臓学会 Japan Society of Hepatology, 2014-11-01
- 著者名:
Terashima, Takeshi Yamashita, Tatsuya Arai, Kuniaki Sunagozaka, Hajime Kitahara, Masaaki Nakagawa, Hidetoshi Kagaya, Takashi Mizukoshi, Eishiro Honda, Masao Kaneko, Shuichi - 掲載情報:
- Hepatology Research
- ISSN:
- 1386-6346
- 巻:
- 44
- 通号:
- 12
- 開始ページ:
- 1179
- 終了ページ:
- 1185
- バージョン:
- author
- 概要:
- Aim: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, although there is no proven therapeutic procedure following the termination of sorafenib, hepatic arterial infusion chemotherapy (HAIC) may be a treatment option in advanced HCC. The aim of this study was to evaluate feasibility and efficacy of HAIC for patients with advanced HCC as subsequent therapy. Methods: We retrospectively evaluated 27 consecutive patients with … advanced HCC who were treated with HAIC following sorafenib between June 2009 and December 2012 at our hospital. Cisplatin (20 mg/m2 per day) was administered via the hepatic artery for 10 min, prior to the continuous administration of 5-fluorouracil (330 mg/m2 per day) over 24 h from days 1-5 and 8-12 and the s.c. administration of pegylated interferon α-2b (1 μg/kg) on days 1, 8, 15, and 22. A treatment cycle consisted of 28 days of drug administration followed by 14 days of rest. Results: The toxicity profile showed that hematological toxicities were common, and grade 3/4 neutropenia and thrombocytopenia were observed (51.9% and 48.1%, respectively). Five patients (18.5%) experienced device-related complications. No unexpected adverse reactions and no treatmentrelated deaths were observed. Partial response was obtained in eight patients (29.6%), and stable disease was noted in nine patients (33.3%). Median progression-free survival and median survival time from initiation of HAIC were 4.0 and 7.6 months, respectively. Conclusions: Because HAIC was well tolerated and exhibited moderate antitumor activity, it is a potentially useful treatment procedure in patients with advanced HCC even after failure of sorafenib. 続きを見る
- URL:
- http://hdl.handle.net/2297/40612
類似資料:
Springer Science and Business Media Deutschland GmbH | |
Wiley-Blackwell |
Springer Science and Business Media Deutschland GmbH |
Japanese Cancer Association / Blackwell Publishing Ltd |